Form 4: Artiva Biotherapeutics Executive's Tax Withholding
Insider Transaction Report
An Artiva Biotherapeutics executive disposed of common stock to cover tax obligations from restricted stock unit vesting.
Summary
- Jennifer Bush, COO, CLO, Secretary, and Compliance Officer of Artiva Biotherapeutics, Inc. (ARTV), reported two dispositions of common stock.
- On May 15, 2025, 1,937 shares of common stock were disposed of at a price of $2.13 per share.
- On August 15, 2025, an additional 6,409 shares of common stock were disposed of at a price of $2.75 per share.
- These dispositions represent shares withheld by Artiva Biotherapeutics to satisfy income tax obligations related to the vesting of restricted stock unit awards.
- Following the May 15, 2025 transaction, Jennifer Bush beneficially owned 157,512 shares of common stock.
- Following the August 15, 2025 transaction, Jennifer Bush beneficially owned 151,103 shares of common stock.
Sentiment
Score: 5
Explanation: The filing reports routine tax-related stock dispositions by an executive, which is a neutral event and does not indicate positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
The filing does not contain any forward-looking statements or guidance.
Industry Context
This Form 4 filing details routine insider transactions related to executive compensation and tax obligations, which are common across all industries, including the biotechnology sector. It does not provide specific insights into broader industry trends or competitive dynamics.
Comparison to Industry Standards
- The disposition of shares to cover tax obligations upon the vesting of restricted stock units is a standard practice for executive compensation across publicly traded companies, including those in the biotechnology industry.
- This type of transaction is a common mechanism for executives to manage their tax liabilities arising from equity awards, aligning with typical compensation structures seen in companies like Moderna (MRNA) or BioNTech (BNTX) where equity is a significant component of executive pay.
Stakeholder Impact
- Shareholders: The disposition of shares for tax purposes is a standard practice and typically has minimal direct impact on the company's share price or overall shareholder value. It reflects a routine aspect of executive compensation.
Key Dates
| Date | Description |
|---|---|
| 05/15/2025 | Date of disposition of 1,937 shares of common stock for tax withholding. |
| 08/15/2025 | Date of disposition of 6,409 shares of common stock for tax withholding. |
| 08/18/2025 | Date the Form 4 was signed by the attorney-in-fact for the reporting person. |
Keywords
Artiva Biotherapeutics, ARTV, SEC Form 4, Insider Transaction, Stock Disposition, Tax Withholding, Restricted Stock Units, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.